Mechanism of enhanced oral absorption of hydrophilic drug incorporated in hydrophobic nanoparticles

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 2709-2717

  Lv, Liang Zhong ^a   Tong, Chen Qi ^a   Yu, Jia ^a   Han, Min ^b   Gao, Jian Qing ^b  

^a ZHEJIANG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

Absorption; Bioavailability; Caco 2 cells; Hydroxysafflor yellow A; Nanoparticles

Indexed keywords

DECANOIC ACID; NANOPARTICLE; OCTANOIC ACID; ORGANIC SOLVENT; PHOSPHOLIPID; PROTEIN ZO1; SAFFLOWER EXTRACT;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CELL STRAIN CACO 2; CELL TRANSPORT; CELL VIABILITY; CHINESE HERB; CONTROLLED STUDY; CYTOTOXICITY; DILUTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG RELEASE; FREEZE FRACTURE; HYDROPHILICITY; HYDROPHOBICITY; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PARTICLE SIZE; RAT; SAFFLOWER; TIGHT JUNCTION; TRANSMISSION ELECTRON MICROSCOPY;

ABSORPTION; BIOAVAILABILITY; CACO-2 CELLS; HYDROXYSAFFLOR YELLOW A; NANOPARTICLES;

ABSORPTION; ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ANALYSIS OF VARIANCE; ANIMALS; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; CELL SURVIVAL; CHALCONE; ENDOCYTOSIS; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; MALE; NANOPARTICLES; QUINONES; RATS; RATS, SPRAGUE-DAWLEY; ZONULA OCCLUDENS-1 PROTEIN;

EID: 84880934069     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S47400     Document Type: Article

References (23)

1. Wang S, Sun M, Ping Q. Enhancing effect of Labrafac Lipophile WL 1349 on oral bioavailability of hydroxysaffor yellow A in rats. Int J Pharm. 2008;358(1-2):198-204.
2. Asada H, Douen T, Waki M, et al. Absorption characteristics of chemically modified-insulin derivatives with various fatty acids in the small and large intestine. J Pharm Sci. 1995;84(6):682-687.
3. Dunn SP, Cooney GF, Kulinsky A, et al. Absorption characteristics of a microemulsion formulation of cyclosporine in de novo pediatric liver transplant recipients. Transplantation. 1995;60(12): 1438-1442.
4. Deshmukh DD, Ravis WR, Betageri GV. Improved delivery of cromolyn from oral proliposomal beads. Int J Pharm. 2008;358(1-2): 128-136.
5. Zang BX, Jin M, Si N, Zhang Y, Wu W, Piao YZ. [Antagonistic effect of hydroxysaffor yellow A on the platelet activating factor receptor]. Yao Xue Xue Bao. 2002;37(9):696-699. Chinese.
6. Zhu H, Wang Z, Ma C, et al. Neuroprotective effects of hydroxysaffor yellow A: in vivo and in vitro studies. Planta Med. 2003;69(5): 429-433.
7. Chu D, Liu W, Huang Z, Liu S, Fu X, Liu K. Pharmacokinetics and excretion of hydroxysaffor yellow A, a potent neuroprotective agent from saffower, in rats and dogs. Planta Med. 2006;72(5):418-423.
8. Qin F, Huang X. Guanxin II (II) for the management of coronary heart disease. Chin J Integr Med. 2009;15(6):472-476.
9. Liu SX, Zhang Y, Wang YF, et al. Upregulation of heme oxygenase-1 expression by hydroxysaffor yellow A conferring protection from anoxia/reoxygenation-induced apoptosis in H9c2 cardiomyocytes. Int J Cardiol. 2012;160(2):95-101.
10. Qi J, Zhuang J, Wu W, et al. Enhanced effect and mechanism of waterin-oil microemulsion as an oral delivery system of hydroxysaffor yellow A. Int J Nanomedicine. 2011;6:985-991.
11. Lv LZ, Tong CQ, Lv Q, et al. Enhanced absorption of hydroxysaffor yellow A using a self-double-emulsifying drug delivery system: in vitro and in vivo studies. Int J Nanomedicine. 2012;7:4099-4107.
12. Hu W, Dong H, Li YZ, Hu XT, Han GJ, Qu YB. A high-throughput model for screening anti-tumor agents capable of promoting polymerization of tubulin in vitro. Acta Pharmacol Sin. 2004;25(6): 775-782.
13. Boukhettala N, Claeyssens S, Bensifi M, et al. Effects of essential amino acids or glutamine deprivation on intestinal permeability and protein synthesis in HCT-8 cells: involvement of GCN2 and mTOR pathways. Amino Acids. 2012;42(1):375-383.
14. Ma TY, Nguyen D, Bui V, Nguyen H, Hoa N. Ethanol modulation of intestinal epithelial tight junction barrier. Am J Physiol. 1999; 276(4 Pt 1):G965-G974.
15. Das S, Ng WK, Kanaujia P, Kim S, Tan RB. Formulation design, preparation and physicochemical characterizations of solid lipid nanoparticles containing a hydrophobic drug: effects of process variables. Colloids Surf B Biointerfaces. 2011;88(1):483-489.
16. Hu K, Cao S, Hu F, Feng J. Enhanced oral bioavailability of docetaxel by lecithin nanoparticles: preparation, in vitro, and in vivo evaluation. Int J Nanomedicine. 2012;7:3537-3545.
17. Roger E, Kalscheuer S, Kirtane A, et al. Folic acid functionalized nanoparticles for enhanced oral drug delivery. Pharmaceutics. 2012;9(7):2103-2110.
18. Tian Y, Yang ZF, Li Y, et al. Pharmacokinetic comparisons of hydroxysaffower yellow A in normal and blood stasis syndrome rats. J Ethnopharmacol. 2010;129(1):1-4.
19. Song L, Zhu Y, Jin M, Zang B. Hydroxysaffor yellow a inhibits lipopolysaccharide-induced infammatory signal transduction in human alveolar epithelial A549 cells. Fitoterapia. 2013;84:107-114.
20. Sun L, Yang L, Xu YW, et al. Neuroprotection of hydroxysaffor yellow A in the transient focal ischemia: inhibition of protein oxidation/ nitration, 12/15-lipoxygenase and blood-brain barrier disruption. Brain Res. 2012;1473:227-235.
21. Zhu HB, Zhang L, Wang ZH, et al. Therapeutic effects of hydroxysaffor yellow A on focal cerebral ischemic injury in rats and its primary mechanisms. J Asian Nat Prod Res. 2005;7(4):607-613.
22. Liu L, Duan JA, Tang Y, et al. Taoren-Honghua herb pair and its main components promoting blood circulation through influencing on hemorheology, plasma coagulation and platelet aggregation. J Ethnopharmacol. 2012;139(2):381-387.
23. Levy MY, Benita S. Drug release from submicronized o/w emulsion-a new in vitro kinetic evaluation model. Int J Pharm. 1990;66(1-3): 29-37.